

Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2019

https://marketpublishers.com/r/M95396F7824EN.html

Date: December 2019 Pages: 2062 Price: US\$ 2,500.00 (Single User License) ID: M95396F7824EN

Abstracts

Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2019

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2019, provides an overview of the Multiple Myeloma (Kahler Disease) (Oncology) pipeline landscape.

Multiple myeloma is a type of cancer that is caused by malignant plasma cells that proliferate in the bone marrow and produce abnormally high amounts of a special protein. The exact cause of multiple myeloma is not clear. Multiple myeloma mainly affects older adults. Symptoms include anemia, bleeding, nerve damage, skin lesions, bone tenderness or pain and kidney failure. Treatment includes chemotherapy, radiation, immunosuppression, and surgery.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide also reviews of key



players involved in therapeutic development for Multiple Myeloma (Kahler Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 10, 103, 107, 1, 11, 159, 29 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 13, 18, 5, 31 and 8 molecules, respectively.

Multiple Myeloma (Kahler Disease) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Multiple Myeloma (Kahler Disease) (Oncology).

The pipeline guide reviews pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Multiple Myeloma (Kahler



Disease) (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Multiple Myeloma (Kahler Disease) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Multiple Myeloma (Kahler Disease) (Oncology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Multiple Myeloma (Kahler Disease) (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Multiple Myeloma (Kahler Disease) (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.



Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.



Contents

Introduction Multiple Myeloma (Kahler Disease) - Overview Multiple Myeloma (Kahler Disease) - Therapeutics Development Multiple Myeloma (Kahler Disease) - Therapeutics Assessment Multiple Myeloma (Kahler Disease) - Companies Involved in Therapeutics Development Multiple Myeloma (Kahler Disease) - Drug Profiles Multiple Myeloma (Kahler Disease) - Dormant Projects Multiple Myeloma (Kahler Disease) - Discontinued Products Multiple Myeloma (Kahler Disease) - Product Development Milestones Appendix



List Of Tables

LIST OF TABLES

Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2019 Number of Products under Development by Companies, H2 2019 Number of Products under Development by Universities/Institutes, H2 2019 Products under Development by Companies, H2 2019 Products under Development by Universities/Institutes, H2 2019 Number of Products by Stage and Target, H2 2019 Number of Products by Stage and Mechanism of Action, H2 2019 Number of Products by Stage and Route of Administration, H2 2019 Number of Products by Stage and Molecule Type, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by 4SC AG, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Aadi Bioscience Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by AbbVie Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by ABL Bio Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Acepodia Biotech Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Actinium Pharmaceuticals Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Active Biotech AB, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Adicet Bio Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Aduro BioTech Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Aeglea BioTherapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Aevi Genomic Medicine Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Affimed GmbH, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by AIMM Therapeutics BV, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Allife Medical Science and Technology Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Allogene Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Altor Bioscience LLC, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Ambrx Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Amgen Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Anhui Anke Biotechnology (Group) Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by APIM Therapeutics AS, H2 2019



Multiple Myeloma (Kahler Disease) - Pipeline by APO-T BV, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Arcellx Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Ascenta Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Ascentage Pharma Group International, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Asclepius Technology Company Group Suzhou Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Aslan Pharmaceuticals Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by AstraZeneca Plc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Atara Biotherapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Auransa Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Aurigene Discovery Technologies Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Autolus Therapeutics Plc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Bantam Pharmaceutical LLC, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Bayer AG, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Beijing Immunochina Medical Science & Technology Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Beijing Sunbio Biotech Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Betta Pharmaceuticals Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by BeyondSpring Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by BioLineRx Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Biomunex Pharmaceuticals, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Biosion Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Biotest AG, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by BioVec Pharma Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by BiVictriX Therapeutics Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Boryung ViGenCell Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Boston Biomedical Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Bristol-Myers Squibb Co, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by CanBas Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by CARsgen Therapeutics Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Cartesian Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by CASI Pharmaceuticals Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Celgene Corp, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Cell Source Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by CellCentric Ltd, H2 2019



Multiple Myeloma (Kahler Disease) - Pipeline by Cellectar Biosciences Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Cellectis SA, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Celleron Therapeutics Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Cellestia Biotech AG, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Cello Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by CellProtect Nordic Pharmaceuticals AB, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Cellular Biomedicine Group Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Celularity Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Celyad SA, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Centrax International Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Checkpoint Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by ChemioCare USA Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Chipscreen Biosciences Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by CiMaas BV, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Cleave Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Constellation Pharmaceuticals Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by CRISPR Therapeutics AG, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by CStone Pharmaceuticals Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Curis Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Curocell Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Cyteir Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Cytonus Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Daiichi Sankyo Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by DC Prime BV, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by DeuteRx LLC, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Diverse Biotech Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Eli Lilly and Co, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Enceladus Pharmaceuticals BV, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by EpicentRx Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Epizyme Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by eTheRNA Immunotherapies NV, H2



2019

2010					
					EUSA Pharma (UK) Ltd, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	ExCellThera Inc, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Exelixis Inc, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	F. Hoffmann-La Roche Ltd, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Fate Therapeutics Inc, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Fera Pharmaceuticals LLC, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Fortis Therapeutics Inc, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Gadeta BV, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Galileo Research srl, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Gamida Cell Ltd, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	GEMoaB Monoclonals GmbH, H2
2019					
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	GemoPharm, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Genenta Science srl, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Genentech Inc, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Genmab A/S, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Gilead Sciences Inc, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	GlaxoSmithKline Plc, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Gliknik Inc, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	GlycoMimetics Inc, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Glycostem Therapeutics BV, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	GlyTR Therapeutics Inc, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	GP Pharm SA, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Gracell Bio, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	GT Biopharma Inc, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	HaemaLogix Pty Ltd, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Harbour BioMed, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Harpoon Therapeutics Inc, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Hebei Senlang Biotechnology Inc Ltd,
H2 2019					
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Heidelberg Pharma AG, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Helix BioPharma Corp, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Helocyte Biosciences Inc, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Hengenix Biotech Inc, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Hillstream BioPharma Inc, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	Hinova Pharmaceuticals Inc, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	HitGen LTD, H2 2019
Multiple Myeloma	(Kahler	Disease) -	Pipeline	by	HRAIN Biotechnology Co Ltd, H2 2019



Multiple Myeloma (Kahler Disease) - Pipeline by HuniLife Biotechnology Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Hutchison MediPharma Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by iCell Gene Therapeutics LLC, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Iceni Pharmaceuticals Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Ichnos Sciences Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by IDAC Theranostics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by IDP Discovery Pharma SL, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by IGF Oncology LLC, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by IGM Biosciences Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by ImmuneTarget Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Immunomedics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Immunotech Biopharm Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Incuron LLC, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Incyte Corp, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Indapta Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Inflection Biosciences Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Inmune Bio Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Innovative Cellular Therapeutics Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Intra-Immusg Pvt Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Inven2 AS, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Inventiva, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by IO Biotech ApS, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Ionova Life Science Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Istesso Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Iterion Therapeutics, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Janpix Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by JN Biosciences LLC, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Johnson & Johnson, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by JSK Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Jubilant Biosys Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Juno Pharmaceuticals Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Juno Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Juventas Cell Therapy Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by JW Pharmaceutical Corp, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Kangpu Biopharmaceuticals Ltd, H2 2019



Multiple Myeloma (Kahler Disease) - Pipeline by Karyopharm Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Kiadis Pharma NV, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Kleo Pharmaceuticals Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Klyss Biotech Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Komipharm International Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Kymab Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Laekna Therapeutics Shanghai Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Leadiant Biosciences Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Les Laboratoires Servier SAS, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Leukogene Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Ligand Pharmaceuticals Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Lokon Pharma AB, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Luye Pharma Group Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Machavert Pharmaceuticals LLC, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Marker Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Max Biopharma Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by MediGene AG, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by MedPacto Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Merck & Co Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Merck KGaA, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Millennium Pharmaceuticals Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Miltenyi Biotec GmbH, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by MimiVax LLC, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Modulation Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Partners AG, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Molecular Templates Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by MolMed SpA, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Momenta Pharmaceuticals Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by MorphoSys AG, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Mustang Bio Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Nanjing Bioheng Biotech Co Ltd, H2 2019



Multiple Myeloma (Kahler Disease) - Pipeline by Nanjing CART Medical Technology Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Nanjing Iaso Biotherapeutics Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Nanjing Legend Biotech Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by NantKwest Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by NBE-Therapeutics AG, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Nektar Therapeutics, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Neonc Technologies Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by NexImmune Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Nippon Kayaku Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Northlake International LLC, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Novartis AG, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Noxxon Pharma AG, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Oncoceutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Oncodesign SA, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by OncoFusion Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Oncology Venture A/S, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Oncolytics Biotech Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Onconova Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by OncoPep Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Oncopeptides AB, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by OncoTartis Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by OncoTherapy Science Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by One World Cannabis Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Otsuka Pharmaceutical Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Peptron Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by PersonGen Anke Cellular Therapeutics Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by PersonGen Biomedicine Suzhou Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Pfizer Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Pharma Mar SA, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Phosplatin Therapeutics LLC, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by PI Therapeutics Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Pimera Inc, H2 2019



Multiple Myeloma (Kahler Disease) - Pipeline by Poseida Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Precision Biosciences Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Prescient Therapeutics Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Progenra Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Quadriga BioSciences Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Qwixel Therapeutics LLC, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Rainier Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Rapa Therapeutics LLC, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by RedHill Biopharma Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Rhizen Pharmaceuticals SA, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Samus Therapeutics LLC, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Sanofi, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Seattle Genetics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Selenity Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by SELLAS Life Sciences Group Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Senhwa Biosciences Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Shanghai Bioray Laboratory Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Shanghai Theorion Pharmaceutical Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Shanghai Yingli Pharmaceutical Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Shenogen Pharma Group Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Shuttle Pharmaceuticals Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Sichuan Kelun Pharmaceutical Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by SignalRx Pharmaceuticals Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by SignPath Pharma Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Sorrento Therapeutics Inc. H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by SpecificiT Pharma Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Sphaera Pharma Pte Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by SpringWorks Therapeutics Inc, H2 2019



Multiple Myeloma (Kahler Disease) - Pipeline by Stemline Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Sunomix Therapeutics, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Surface Oncology Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Sutro Biopharma Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by T-Knife GmbH, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by TaiGen Biotechnology Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Taiho Pharmaceutical Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by TaiRx Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Targazyme Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by TeneoBio Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Terpenoid Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Tiziana Life Sciences Plc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Tmunity Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Tolero Pharmaceuticals Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Transgene Biotek Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Trillium Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Triumvira Immunologics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Ube Industries Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Unum Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Vaccibody AS, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Vaxil Bio Therapeutics Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Vichem Chemie Research Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Visterra Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Vycellix Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Vyriad Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by WindMIL Therapeutics Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Wuhan Bio-Raid Biotechnology Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Wuhan YZY Biopharma Co Ltd, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by XEME BioPharma Inc, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Xiangxue Life Sciences, H2 2019 Multiple Myeloma (Kahler Disease) - Pipeline by Zovis Pharmaceuticals, H2 2019 Multiple Myeloma (Kahler Disease) - Dormant Projects, H2 2019



Multiple Myeloma (Kahler Disease) - Discontinued Products, H2 2019



List Of Figures

LIST OF FIGURES

Number of Products under Development for Multiple Myeloma (Kahler Disease), H2 2019 Number of Products under Development by Companies, H2 2019 Number of Products under Development by Universities/Institutes, H2 2019 Number of Products by Top 10 Targets, H2 2019 Number of Products by Stage and Top 10 Targets, H2 2019 Number of Products by Top 10 Mechanism of Actions, H2 2019 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019 Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019 Number of Products by Top 10 Routes of Administration, H2 2019 Number of Products by Stage and Top 10 Routes of Administration, H2 2019 Number of Products by Stage and Top 10 Routes of Administration, H2 2019 Number of Products by Top 10 Molecule Types, H2 2019 Number of Products by Stage and Top 10 Molecule Types, H2 2019

COMPANIES MENTIONED

4SC AG

A. Menarini Industrie Farmaceutiche Riunite Srl Aadi Bioscience Inc AbbVie Inc ABL Bio Inc Acepodia Biotech Inc Actinium Pharmaceuticals Inc Active Biotech AB Adicet Bio Inc Aduro BioTech Inc Aeglea BioTherapeutics Inc Aevi Genomic Medicine Inc Affimed GmbH **AIMM Therapeutics BV** Allife Medical Science and Technology Co Ltd Allogene Therapeutics Inc Altor Bioscience LLC Ambrx Inc Amgen Inc Anhui Anke Biotechnology (Group) Co Ltd



APIM Therapeutics AS APO-T BV Arcellx Inc Ascenta Therapeutics Inc Ascentage Pharma Group International Asclepius Technology Company Group Suzhou Co Ltd Aslan Pharmaceuticals Ltd AstraZeneca Plc Atara Biotherapeutics Inc Auransa Inc Aurigene Discovery Technologies Ltd Autolus Therapeutics Plc **Bantam Pharmaceutical LLC** Bayer AG Beijing Immunochina Medical Science & Technology Co Ltd Beijing Sunbio Biotech Co Ltd Betta Pharmaceuticals Co Ltd **BeyondSpring Inc BioLineRx Ltd Biomunex Pharmaceuticals Biosion Inc Biotest AG BioVec Pharma Inc BiVictriX Therapeutics Ltd** Boryung ViGenCell Inc **Boston Biomedical Inc** Bristol-Myers Squibb Co CanBas Co Ltd **CARsgen Therapeutics Ltd Cartesian Therapeutics Inc CASI** Pharmaceuticals Inc Celgene Corp Cell Source Inc CellCentric Ltd Cellectar Biosciences Inc Cellectis SA **Celleron Therapeutics Ltd** Cellestia Biotech AG Cello Therapeutics Inc




- CellProtect Nordic Pharmaceuticals AB
- Cellular Biomedicine Group Inc
- Celularity Inc
- Celyad SA
- Centrax International Inc
- **Checkpoint Therapeutics Inc**
- ChemioCare USA Inc
- Chipscreen Biosciences Ltd
- Chong Kun Dang Pharmaceutical Corp
- CiMaas BV
- **Cleave Therapeutics Inc**
- Constellation Pharmaceuticals Inc
- **CRISPR** Therapeutics AG
- CStone Pharmaceuticals Co Ltd
- Curis Inc
- Curocell Inc
- Cyclacel Pharmaceuticals Inc
- Cyteir Therapeutics Inc
- Cytonus Therapeutics Inc
- Daiichi Sankyo Co Ltd
- DC Prime BV
- DeuteRx LLC
- **Diverse Biotech Inc**
- Eli Lilly and Co
- Enceladus Pharmaceuticals BV
- EpicentRx Inc
- Epizyme Inc
- eTheRNA Immunotherapies NV
- EUSA Pharma (UK) Ltd
- ExCellThera Inc
- Exelixis Inc
- F. Hoffmann-La Roche Ltd
- Fate Therapeutics Inc
- Fera Pharmaceuticals LLC
- Fortis Therapeutics Inc
- Gadeta BV
- Galileo Research srl
- Gamida Cell Ltd
- GEMoaB Monoclonals GmbH



GemoPharm

- Genenta Science srl
- Genentech Inc
- Genmab A/S
- Gilead Sciences Inc
- GlaxoSmithKline Plc
- Gliknik Inc
- **GlycoMimetics Inc**
- **Glycostem Therapeutics BV**
- GlyTR Therapeutics Inc
- GP Pharm SA
- Gracell Bio
- GT Biopharma Inc
- HaemaLogix Pty Ltd
- Harbour BioMed
- Harpoon Therapeutics Inc
- Hebei Senlang Biotechnology Inc Ltd
- Heidelberg Pharma AG
- Helix BioPharma Corp
- Helocyte Biosciences Inc
- Hengenix Biotech Inc
- Hillstream BioPharma Inc
- Hinova Pharmaceuticals Inc
- HitGen LTD
- HRAIN Biotechnology Co Ltd
- HuniLife Biotechnology Inc
- Hutchison MediPharma Ltd
- iCell Gene Therapeutics LLC
- Iceni Pharmaceuticals Ltd
- Ichnos Sciences Inc
- **IDAC** Theranostics Inc
- IDP Discovery Pharma SL
- IGF Oncology LLC
- IGM Biosciences Inc
- ImmuneTarget Inc
- Immunomedics Inc
- Immunotech Biopharm Ltd
- Incuron LLC
- Incyte Corp





Indapta Therapeutics Inc Inflection Biosciences Ltd Inmune Bio Inc Innovative Cellular Therapeutics Co Ltd Intra-Immusg Pvt Ltd Inven2 AS Inventiva **IO Biotech ApS** Ionova Life Science Co Ltd Istesso Ltd **Iterion Therapeutics** Janpix Inc Jiangsu Hengrui Medicine Co Ltd **JN Biosciences LLC** Johnson & Johnson **JSK** Therapeutics Inc Jubilant Biosys Ltd Juno Pharmaceuticals Inc Juno Therapeutics Inc Juventas Cell Therapy Ltd JW Pharmaceutical Corp Kangpu Biopharmaceuticals Ltd Karyopharm Therapeutics Inc **Kiadis Pharma NV** Kleo Pharmaceuticals Inc Klyss Biotech Inc Komipharm International Co Ltd Kymab Ltd Laekna Therapeutics Shanghai Co Ltd Leadiant Biosciences Inc Les Laboratoires Servier SAS Leukogene Therapeutics Inc Ligand Pharmaceuticals Inc Lokon Pharma AB Luve Pharma Group Ltd Machavert Pharmaceuticals LLC Marker Therapeutics Inc Max Biopharma Inc MediGene AG



MedPacto Inc Merck & Co Inc Merck KGaA **Millennium Pharmaceuticals Inc** Miltenyi Biotec GmbH MimiVax LLC Modulation Therapeutics Inc Molecular Partners AG Molecular Templates Inc MolMed SpA Momenta Pharmaceuticals Inc MorphoSys AG Mustang Bio Inc Nanjing Bioheng Biotech Co Ltd Nanjing CART Medical Technology Co Ltd Nanjing Iaso Biotherapeutics Co Ltd Nanjing Legend Biotech Co Ltd NantKwest Inc **NBE-Therapeutics AG Nektar Therapeutics** Neonc Technologies Inc NexImmune Inc Nippon Kayaku Co Ltd Northlake International LLC Novartis AG Noxxon Pharma AG **Oncoceutics Inc Oncodesign SA OncoFusion Therapeutics Inc** Oncology Venture A/S **Oncolytics Biotech Inc Onconova Therapeutics Inc** OncoPep Inc **Oncopeptides AB OncoTartis Inc OncoTherapy Science Inc** One World Cannabis Ltd Ono Pharmaceutical Co Ltd Otsuka Pharmaceutical Co Ltd



Peptron Inc PersonGen Anke Cellular Therapeutics Co Ltd PersonGen Biomedicine Suzhou Co Ltd Pfizer Inc Pharma Mar SA Phosplatin Therapeutics LLC PI Therapeutics Ltd Pimera Inc **Poseida Therapeutics Inc Precision Biosciences Inc Prescient Therapeutics Ltd** Progenra Inc Quadriga BioSciences Inc **Qwixel Therapeutics LLC Rainier Therapeutics Inc** Rapa Therapeutics LLC RedHill Biopharma Ltd **Regeneron Pharmaceuticals Inc Rhizen Pharmaceuticals SA** Samus Therapeutics LLC Sanofi Seattle Genetics Inc Selenity Therapeutics Inc SELLAS Life Sciences Group Inc Senhwa Biosciences Inc Shanghai Bioray Laboratory Inc Shanghai Theorion Pharmaceutical Co Ltd Shanghai Unicar-Therapy Bio-Medicine Technology Co Ltd Shanghai Yingli Pharmaceutical Co Ltd Shenogen Pharma Group Ltd Shuttle Pharmaceuticals Inc Sichuan Kelun Pharmaceutical Co Ltd SignalRx Pharmaceuticals Inc

SignPath Pharma Inc



I would like to order

Product name: Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2019 Product link: <u>https://marketpublishers.com/r/M95396F7824EN.html</u>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery) If you want to order Corporate License or Hard Copy, please, contact our Customer Service: <u>info@marketpublishers.com</u>

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <u>https://marketpublishers.com/r/M95396F7824EN.html</u>